Cytovation AS | MedPath

Melanoma Treatment Landscape Evolves with Novel Immunotherapies and Targeted Approaches

7 months ago

• The FDA granted fast-track approval to Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, for metastatic melanoma patients who have failed other treatments, marking a significant advancement in cellular immunotherapy. • Neoadjuvant immunotherapy has become the standard of care for stage III melanoma patients with resectable tumors, as highlighted at the European Society for Medical Oncology (ESMO) Congress. • Over 170 melanoma pipeline therapies are under development by 150+ companies, including IO Biotech, Moderna, Merck, and BioNTech, targeting various stages and mechanisms of the disease.